Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy

Authors: Khalilullah Mia-Jan, So Young Jung, Ik-Yong Kim, Sung Soo Oh, EunHee Choi, Sei Jin Chang, Tae Young Kang, Mee-Yon Cho

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal cancers (CRCs) is not clear yet.

Methods

We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR. CD133 promoter methylation was quantified by pyrosequencing.

Results

The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer (p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103). However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95% CI 0.052-0.299). But the patients with CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR 0.500, 95% CI 0.247-1.015).

Conclusions

In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy although it is not an independent prognostic factor.
Appendix
Available only for authorised users
Literature
1.
Lin H, Schagat T: Neuroblasts: a model for the asymmetric division of stem cells. Trends Genet. 1997, 13: 33-39. 10.1016/S0168-9525(96)10050-0.CrossRefPubMed
2.
McCulloch EA, Till JE: Perspectives on the properties of stem cells. Nat Med. 2005, 11: 1026-1028. 10.1038/nm1005-1026.CrossRefPubMed
3.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed
4.
Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 2007, 58: 267-284. 10.1146/annurev.med.58.062105.204854.CrossRefPubMed
5.
Dick JE: Looking ahead in cancer stem cell research. Nat Biotechnol. 2009, 27: 44-46. 10.1038/nbt0109-44.CrossRefPubMed
6.
Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, Mader RM: Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. Exp Cell Res. 2010, 316: 3172-3181. 10.1016/j.yexcr.2010.09.003.CrossRefPubMed
7.
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007, 104: 10158-10163. 10.1073/pnas.0703478104.CrossRefPubMedPubMedCentral
8.
Patel SA, Ndabahaliye A, Lim PK, Milton R, Rameshwar P: Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (London). 2010, 2: 1-11.
9.
Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 2010, 126: 950-958.PubMed
10.
Yu JW, Zhang P, Wu JG, Wu SH, Li XQ, Wang ST, Lu RQ, Ni XC, Jiang BJ: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res. 2010, 29: 141-10.1186/1756-9966-29-141.CrossRefPubMedPubMedCentral
11.
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008, 99: 100-109. 10.1038/sj.bjc.6604437.CrossRefPubMedPubMedCentral
12.
Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R: CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010, 10: 1182-1190. 10.4161/cbt.10.11.13664.CrossRefPubMed
13.
Missol-Kolka E, Karbanova J, Janich P, Haase M, Fargeas CA, Huttner WB, Corbeil D: Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate. 2011, 71: 254-267. 10.1002/pros.21239.CrossRefPubMed
14.
Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol. 2010, 8: 147-10.1186/1477-7827-8-147.CrossRefPubMedPubMedCentral
15.
Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y: CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas. 2009, 38: e207-e214. 10.1097/MPA.0b013e3181bb5037.CrossRefPubMed
16.
Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A: Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood. 2009, 113: 3287-3296. 10.1182/blood-2008-04-154187.CrossRefPubMed
17.
Cheng RB, Ma RJ, Wang ZK, Yang SJ, Lin XZ, Rong H, Ma Y: PTEN status is related to cell proliferation and self-renewal independent of CD133 phenotype in the glioma-initiating cells. Mol Cell Biochem. 2011, 349: 149-157. 10.1007/s11010-010-0669-1.CrossRefPubMed
18.
Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, Ugolotti E, Milanaccio C, Pignatelli S, Ferraro M: High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro Oncol. 2011, 13: 500-508. 10.1093/neuonc/nor022.CrossRefPubMedPubMedCentral
19.
Shmelkov SV, St Clair R, Lyden D, Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 2005, 37: 715-719. 10.1016/j.biocel.2004.08.010.CrossRefPubMed
20.
Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, Zhang X, Pan ZZ, Wan DS, Zeng YX: Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med. 2009, 7: 56-10.1186/1479-5876-7-56.CrossRefPubMedPubMedCentral
21.
Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 2004, 103: 2055-2061. 10.1182/blood-2003-06-1881.CrossRefPubMed
22.
Pleshkan VV, Vinogradova TV, Sverdlov ED: Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. Biochim Biophys Acta. 2008, 1779: 599-605. 10.1016/j.bbagrm.2008.06.002.CrossRefPubMed
23.
Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S: Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res. 2008, 18: 1037-1046. 10.1038/cr.2008.270.CrossRefPubMed
24.
Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ: Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?. Biochem Biophys Res Commun. 2007, 355: 855-859. 10.1016/j.bbrc.2007.01.159.CrossRefPubMed
25.
Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A: The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009, 219: 427-434. 10.1002/path.2597.CrossRefPubMed
26.
Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, Miki C, Kusunoki M: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009, 16: 3488-3498. 10.1245/s10434-009-0617-z.CrossRefPubMed
27.
Artells R, Moreno I, Diaz T, Martinez F, Gel B, Navarro A, Ibeas R, Moreno J, Monzo M: Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer. 2010, 46: 642-649. 10.1016/j.ejca.2009.11.003.CrossRefPubMed
28.
Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E: CD133(−) Cells, Derived From a Single Human Colon Cancer Cell Line, Are More Resistant to 5-Fluorouracil (FU) Than CD133(+) Cells, Dependent on the beta1-Integrin Signaling. J Surg Res. 2012, 175: 278-288. 10.1016/j.jss.2011.03.076.CrossRefPubMed
29.
30.
Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008, 14: 6751-6760. 10.1158/1078-0432.CCR-08-1034.CrossRefPubMed
31.
Jeon YK, Kim SH, Choi SH, Kim KH, Yoo BC, Ku JL, Park JG: Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. World J Gastroenterol. 2010, 16: 3153-3160. 10.3748/wjg.v16.i25.3153.CrossRefPubMedPubMedCentral
32.
Todaro M, Francipane MG, Medema JP, Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010, 138: 2151-2162. 10.1053/j.gastro.2009.12.063.CrossRefPubMed
33.
McDonald SA, Preston SL, Lovell MJ, Wright NA, Jankowski JA: Mechanisms of disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol Hepatol. 2006, 3: 267-274. 10.1038/ncpgasthep0473.CrossRefPubMed
34.
Huh JW, Park YS, Lee JH, Kim HR, Shin MG, Kim YJ: CD133 mRNA expression and microsatellite instability in colorectal carcinoma. J Surg Oncol. 2010, 102: 765-770. 10.1002/jso.21734.CrossRefPubMed
35.
Liao Y, Hu X, Huang X, He C: Quantitative analyses of CD133 expression facilitate researches on tumor stem cells. Biol Pharm Bull. 2010, 33: 738-742. 10.1248/bpb.33.738.CrossRefPubMed
36.
Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008, 99: 1578-1583. 10.1111/j.1349-7006.2008.00849.x.CrossRefPubMed
37.
Horst D, Kriegl L, Engel J, Kirchner T, Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008, 99: 1285-1289. 10.1038/sj.bjc.6604664.CrossRefPubMedPubMedCentral
38.
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008, 118: 2111-2120.PubMedPubMedCentral
39.
Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, Salto-Tellez M: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010, 23: 450-457. 10.1038/modpathol.2009.181.CrossRefPubMed
40.
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997, 90: 5002-5012.PubMed
41.
Green WB, Slovak ML, Chen IM, Pallavicini M, Hecht JL, Willman CL: Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia. 1999, 13: 1960-1971. 10.1038/sj.leu.2401596.CrossRefPubMed
42.
Bidlingmaier S, Zhu X, Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 2008, 86: 1025-1032. 10.1007/s00109-008-0357-8.CrossRef
43.
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997, 90: 5013-5021.PubMed
44.
Mizrak D, Brittan M, Alison MR: CD133: molecule of the moment. J Pathol. 2008, 214: 3-9. 10.1002/path.2283.CrossRefPubMed
Metadata
Title
CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy
Authors
Khalilullah Mia-Jan
So Young Jung
Ik-Yong Kim
Sung Soo Oh
EunHee Choi
Sei Jin Chang
Tae Young Kang
Mee-Yon Cho
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-166

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Case report

Malignant extra-adrenal pancreatic paraganglioma: case report and literature review

Research article

Classification tree analysis to enhance targeting for follow-up exam of colorectal cancer screening

Research article

“Unique trend” and “contradictory trend” in discrimination of primary synchronous lung cancer and metastatic lung cancer

Technical advance

A new assay for measuring chromosome instability (CIN) and identification of drugs that elevate CIN in cancer cells

Research article

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers

Research article

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits